Clinical trial reveals positive results for treating children with rare gliomas
Tafinlar and Mekinist led to a 56% overall response rate in children with BM-HGG
Read More
Tag: BRAF-mutated low-grade paediatric gliomas
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
